VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
Nasal spray to treat anxiety moves forward with global phase 3 trial
VistaGen Therapeutics, Inc. (VTGN) Message Board | InvestorsHub
PH94B Neuroactive Nasal Spray, a Potential On-Demand Treatment for Social Anxiety Disorder - YouTube
Nasal spray to treat social anxiety disorder lacks abuse potential: FDA
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B | Business Wire
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
Social Anxiety Disorder | Vistagen Therapeutics, Inc
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
Fasedienol - Wikipedia
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder | S&P Global Market Intelligence
PDF) Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder: L iebowitz et al.
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
VistaGen can't puff out phase 3 success for social anxiety spray
VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety | Seeking Alpha
:%0A%0APH94B%20Nasal%20Spray%20for%20Anxiety%20Disorders.png?md=1 "PH94B Nasal Spray for Anxiety Disorders Clinical Trial 2022 | Power")
PH94B Nasal Spray for Anxiety Disorders Clinical Trial 2022 | Power
Psych News Alert: Experimental Nasal Spray May Treat Social Anxiety Disorder, Study Indicates
Social Interaction Challenge, Minute-by-Minute Subjective Units of... | Download Scientific Diagram
VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines
Latest Pharma News Updates | VistaGen, Merck, CAMP4, Wugen, Incyte
